A prospective multicenter validation study for a novel angiography-derived physiological assessment software: Rationale and design of the radiographic imaging validation and evaluation for Angio-iFR (ReVEAL iFR) study - 09/07/21
, Manesh R. Patel, MD d, Javier Escaned, MD, PhD e, Takashi Akasaka, MD, PhD f, Martijn A. van Lavieren, MSc a, g, Christian Haase, PhD g, Michael Grass, PhD g, Norihiro Kogame, MD a, Hironori Hara, MD a, b, Hideyuki Kawashima, MD a, b, Joanna J. Wykrzykowska, MD, PhD h, Jan J. Piek, MD, PhD a, Scot Garg, MD, PhD i, Neil O'Leary, PhD b, Becky Inderbitzen, MSE g, Yoshinobu Onuma, MD, PhD bBackground |
Angiography-derived physiological assessment of coronary lesions has emerged as an alternative to wire-based assessment aiming at less-invasiveness and shorter procedural time as well as cost effectiveness in physiology-guided decision making. However, current available image-derived physiology software have limitations including the requirement of multiple projections and are time consuming.
Methods/Design |
The ReVEAL iFR (Radiographic imaging Validation and EvALuation for Angio-iFR) trial is a multicenter, multicontinental, validation study which aims to validate the diagnostic accuracy of the Angio-iFR medical software device (Philips, San Diego, US) in patients undergoing angiography for Chronic Coronary Syndrome (CCS). The Angio-iFR will enable operators to predict both the iFR and FFR value within a few seconds from a single projection of cine angiography by using a lumped parameter fluid dynamics model. Approximately 440 patients with at least one de-novo 40% to 90% stenosis by visual angiographic assessment will be enrolled in the study. The primary endpoint is the sensitivity and specificity of the iFR and FFR for a given lesion compared to the corresponding invasive measures. The enrollment started in August 2019, and was completed in March 2021.
Summary |
The Angio-iFR system has the potential of simplifying physiological evaluation of coronary stenosis compared with available systems, providing estimates of both FFR and iFR. The ReVEAL iFR study will investigate the predictive performance of the novel Angio-iFR software in CCS patients. Ultimately, based on its unique characteristics, the Angio-iFR system may contribute to improve adoption of functional coronary assessment and the workflow in the catheter laboratory.
Le texte complet de cet article est disponible en PDF.Mots-clés : Coronary artery disease, iFR, FFR, Study design, ReVEAL iFR, Angio-iFR, QFR
Abbreviations : ACS, AHA, CCS, ESC, FFR, iFR, ITT, PCI, PP, QCA, Pd, Pa
Plan
Vol 239
P. 19-26 - septembre 2021 Retour au numéro
Article précédent
- Potential impact of the steroid hormone, vitamin D, on the vasculature
- Yin Tintut, Linda L. Demer
- Rationale and design of the intravenous iron for treatment of anemia before cardiac surgery trial
- Paul S. Myles, Toby Richards, Andrew Klein, Julian Smith, Erica M. Wood, Stephane Heritier, David McGiffin, Silva Zavarsek, Joel Symons, Zoe K. McQuilten, Robert A. Baker, Keyvan Karkouti, Sophia Wallace, the ANZCA Clinical Trials Network
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?